2-M-Hydroxy Paclitaxel, with the CAS number 132160-31-7, is a derivative of the well-known chemotherapeutic agent paclitaxel, which is primarily used in the treatment of various cancers, including ovarian and breast cancer. This compound features a hydroxyl group at the 2-position of the paclitaxel structure, which may influence its pharmacological properties, including solubility, stability, and biological activity. The presence of the hydroxyl group can enhance its interaction with biological targets, potentially improving its efficacy or altering its side effect profile compared to the parent compound. 2-M-Hydroxy Paclitaxel is characterized by its complex molecular structure, which includes a taxane core, a side chain, and various functional groups that contribute to its activity. Research into this compound may focus on its mechanism of action, therapeutic potential, and how modifications to its structure can lead to improved outcomes in cancer treatment. As with many derivatives, understanding its pharmacokinetics and toxicity is crucial for its development as a therapeutic agent.

2-M-HYDROXY PACLITAXEL

132160-31-7: 2-M-Hydroxy Paclitaxel, with the CAS number 132160-31-7, is a derivative of the well-known chemotherapeutic agent paclitaxel, which is primarily used in the treatment of various cancers, including ovarian and breast cancer. This compound features a hydroxyl group at the 2-position of the paclitaxel structure, which may influence its pharmacological properties, including solubility, stability, and biological activity. The presence of the hydroxyl group can enhance its interaction with biological targets, potentially improving its efficacy or altering its side effect profile compared to the parent compound. 2-M-Hydroxy Paclitaxel is characterized by its complex molecular structure, which includes a taxane core, a side chain, and various functional groups that contribute to its activity. Research into this compound may focus on its mechanism of action, therapeutic potential, and how modifications to its structure can lead to improved outcomes in cancer treatment. As with many derivatives, understanding its pharmacokinetics and toxicity is crucial for its development as a therapeutic agent.

CAS 132160-31-7

2-M-HYDROXY PACLITAXEL

2-m-Hydroxy(benzoyl) Paclitaxel

Ref: TR-H949475